GLP-1 Study

Patent-pending Digexin is backed by two double blind placebo controlled human studies as well as open label and placebo comparison studies with results showing improved digestion and enhanced mood.

Overview GLP-1 Study

The Digestive Performance Solution Built for the GLP-1 Era

This study evaluated Digexin® in a randomized, double-blind, placebo-controlled human clinical trial to assess its impact on circulating glucagon-like peptide-1 (GLP-1), a gut-derived hormone involved in digestive signaling and metabolic communication.

The primary endpoint was change in circulating GLP-1 levels from baseline over the study period.

Study pending publication.

Length of Study:

21 days

Study Size:

12 healthy adults

Population:

Adults GLP-1 users experiencing digestive discomfort (confirm from CSR)

Dose:

500mg Digexin daily

Primary Endpoint:

Circulating GLP-1 levels

Secondary Measures:

Digestive function, bowel movement patterns, GI symptoms

Safety Monitoring:

Adverse events and laboratory parameters were tracked throughout

Constipation Relief

94% after 14 days of supplementation

Decrease Bloating

91% after 14 days of supplementation

Complete Bowel Movements

127% after 14 days of supplementation

Transit Time

4 hours faster with Digexin

Enhance Quality of Life

97% after 60 days of supplementation

Primary Outcome: Circulating GLP-1

Participants receiving Digexin demonstrated a statistically significant increase in circulating GLP-1 compared to placebo over the study period.

GLP-1 is secreted by intestinal L-cells in response to nutrient exposure and plays a key role in:

Digestive signaling
Gastric motility regulation
Communication between the gut and peripheral systems

The observed increase suggests activation of endogenous gut-derived signaling pathways rather than external stimulation.

Digestive Signaling & Enteroendocrine Response

GLP-1 is part of a broader enteroendocrine network that integrates:

Nutrient sensing
Motility regulation
Satiety signaling
Metabolic communication

The modulation observed in this study is consistent with Digexin’s ability to engage intestinal signaling pathways through botanical mechanisms—without acting as a synthetic hormone or receptor agonist.

Clinical Relevance in GLP-1 Users

In a separate completed study in individuals using GLP-1 therapies, Digexin demonstrated meaningful improvements in digestive tolerance and comfort.

Key observations included:

Significant reduction in GI symptoms such as constipation, bloating, and gas
Increased bowel movement frequency (from ~3/week toward ~7/week)
Improved digestive regularity and completeness
Benefits observed within 7 days
Well tolerated with no serious adverse events reported

This positions Digexin as a supportive solution for individuals experiencing digestive disruption associated with GLP-1 therapy—without interfering with the pharmacologic mechanism.

Mechanistic Context

Digexin combines okra fruit (Abelmoschus esculentus) and ashwagandha root (Withania somnifera), working across multiple complementary pathways:

Modulation of stress-related digestive signaling
Support for coordinated peristalsis and transit
Engagement of gut-derived hormonal signaling (including GLP-1)
Support for intestinal barrier and digestive comfort

These pathways reflect a systems-level approach to digestive regulation rather than a single-target mechanism.

Safety & Tolerability

Digexin was well tolerated throughout the study:

No serious adverse events reported
No clinically significant safety concerns observed
Laboratory parameters remained within normal ranges